Retrieve available abstracts of 12 articles: HTML format
Single Articles
August 2025
APOLO AB, Atiq S, Kydd AR, Chelluri R, et al Top advances of the year: Bladder cancer.
Cancer. 2025;131:e70020. PubMedAbstract available
July 2025
NIERENGARTEN MB FDA approves durvalumab for perioperative immunotherapy for patients with
muscle-invasive bladder cancer: In a prespecified analysis, the trial
demonstrated a statistically significant improvement in event-free survival and
overall survival.
Cancer. 2025;131:e35912. PubMed
LAZAROVICH A, Sweis RF The current and future role of systemic therapy in non-muscle-invasive bladder
cancer.
Cancer. 2025;131:e35966. PubMedAbstract available
January 2025
O'DONNELL PH, Loriot Y, Csoszi T, Matsubara N, et al Efficacy and safety of pembrolizumab in patients with advanced urothelial
carcinoma deemed potentially ineligible for platinum-containing chemotherapy:
Post hoc analysis of KEYNOTE-052 and LEAP-011.
Cancer. 2025;131:e35601. PubMedAbstract available
November 2024
BERGEROT CD, Schmitz KH, Crane TE, Klaassen Z, et al Comprehensive care for patients with bladder cancer: Addressing the interplay of
physical, nutritional, and emotional well-being.
Cancer. 2024 Nov 28. doi: 10.1002/cncr.35670. PubMed
BRIGGS LG, Parke SC, Beck KL, Sinha D, et al Prehabilitative/rehabilitative exercise, nutrition, and psychological support for
bladder cancer: A scoping review of randomized clinical trials.
Cancer. 2024 Nov 2. doi: 10.1002/cncr.35608. PubMedAbstract available
October 2024
NATHAN KK, Follmer KM, Nash MG, Wolff EM, et al The Comparison of Intravesical Therapy and Surgery as Treatment Options for
Bladder Cancer (CISTO) study: Lessons learned about management and patient
enrollment in a large, pragmatic, patient-centered trial.
Cancer. 2024 Oct 14. doi: 10.1002/cncr.35600. PubMedAbstract available
September 2024
NIERENGARTEN MB Promising new treatment shows potential for high-risk bladder cancer.
Cancer. 2024;130:3075. PubMed
July 2024
NIERENGARTEN MB New standard of care for bladder cancer.
Cancer. 2024;130:2407. PubMed
MARTINI DJ, Case KB, Gratz D, Pellegrini K, et al PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with
divergent differentiation.
Cancer. 2024 Jul 3. doi: 10.1002/cncr.35465. PubMedAbstract available
February 2024
NIERENGARTEN MB Major advancements in first-line treatments for advanced urothelial cancer.
Cancer. 2024;130:333-334. PubMed
January 2024
PEIPERT JD, Chang J, Li S, di Pietro A, et al Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom
Index (NFBlSI-18) in patients with advanced urothelial cancer.
Cancer. 2024;130:31-40. PubMedAbstract available